Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study

Abstract Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are few data outside clinical trials evaluating their prevalence and impact of elbasvir/grazoprevir. A mul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claudia Palladino, Marta Sánchez-Carrillo, Irene Mate-Cano, Sonia Vázquez-Morón, Ma Ángeles Jimenez-Sousa, Mónica Gutiérrez-Rivas, Salvador Resino, Verónica Briz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dd2bac3ede674d558068c3f99056c3d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd2bac3ede674d558068c3f99056c3d8
record_format	dspace
spelling	oai:doaj.org-article:dd2bac3ede674d558068c3f99056c3d82021-12-02T11:52:41ZLow frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study10.1038/s41598-017-02968-72045-2322https://doaj.org/article/dd2bac3ede674d558068c3f99056c3d82017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02968-7https://doaj.org/toc/2045-2322Abstract Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are few data outside clinical trials evaluating their prevalence and impact of elbasvir/grazoprevir. A multicenter cross-sectional study of 617 HCV-GT1a-infected individuals attended in 84 Spanish hospitals from the 17 Autonomous Communities and two Autonomous cities was performed. HCV population sequencing was used to identify RASs to elbasvir and the mutational pattern and drug sensitivity were confirmed by geno2pheno[HCV]. Viruses bearing RASs to elbasvir were present in 6.2% of HCV-GT1a infected patients. The most common RASs were the Y93C/H/N and Q30E/H/R (2.4% and 2.3%; respectively). Only 3.4% of patients had viruses with RASs that confer reduced susceptibility to elbasvir by geno2pheno[HCV] that identified exclusively the positions Q30H/R (n = 7) and Y93C/H/N (n = 8) as single mutations and Q30H + Y93H (n = 4) and Q30R + Y93H (n = 2) as double mutations considered as RASs to elbasvir. Lower prevalence of RASs to elbasvir in our HCV-GT1a-Spanish cohort was observed than reported previously in clinical trials. This information may be essential to guiding the implementation of elbasvir/grazoprevir in Spain, expected at the beginning of 2017 and the management of GT1a-infected patients.Claudia PalladinoMarta Sánchez-CarrilloIrene Mate-CanoSonia Vázquez-MorónMa Ángeles Jimenez-SousaMónica Gutiérrez-RivasSalvador ResinoVerónica BrizNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-6 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Claudia Palladino Marta Sánchez-Carrillo Irene Mate-Cano Sonia Vázquez-Morón Ma Ángeles Jimenez-Sousa Mónica Gutiérrez-Rivas Salvador Resino Verónica Briz Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
description	Abstract Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are few data outside clinical trials evaluating their prevalence and impact of elbasvir/grazoprevir. A multicenter cross-sectional study of 617 HCV-GT1a-infected individuals attended in 84 Spanish hospitals from the 17 Autonomous Communities and two Autonomous cities was performed. HCV population sequencing was used to identify RASs to elbasvir and the mutational pattern and drug sensitivity were confirmed by geno2pheno[HCV]. Viruses bearing RASs to elbasvir were present in 6.2% of HCV-GT1a infected patients. The most common RASs were the Y93C/H/N and Q30E/H/R (2.4% and 2.3%; respectively). Only 3.4% of patients had viruses with RASs that confer reduced susceptibility to elbasvir by geno2pheno[HCV] that identified exclusively the positions Q30H/R (n = 7) and Y93C/H/N (n = 8) as single mutations and Q30H + Y93H (n = 4) and Q30R + Y93H (n = 2) as double mutations considered as RASs to elbasvir. Lower prevalence of RASs to elbasvir in our HCV-GT1a-Spanish cohort was observed than reported previously in clinical trials. This information may be essential to guiding the implementation of elbasvir/grazoprevir in Spain, expected at the beginning of 2017 and the management of GT1a-infected patients.
format	article
author	Claudia Palladino Marta Sánchez-Carrillo Irene Mate-Cano Sonia Vázquez-Morón Ma Ángeles Jimenez-Sousa Mónica Gutiérrez-Rivas Salvador Resino Verónica Briz
author_facet	Claudia Palladino Marta Sánchez-Carrillo Irene Mate-Cano Sonia Vázquez-Morón Ma Ángeles Jimenez-Sousa Mónica Gutiérrez-Rivas Salvador Resino Verónica Briz
author_sort	Claudia Palladino
title	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
title_short	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
title_full	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
title_fullStr	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
title_full_unstemmed	Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
title_sort	low frequency of ns5a relevant resistance-associated substitutions to elbasvir among hepatitis c virus genotype 1a in spain: a cross-sectional study
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/dd2bac3ede674d558068c3f99056c3d8
work_keys_str_mv	AT claudiapalladino lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT martasanchezcarrillo lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT irenematecano lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT soniavazquezmoron lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT maangelesjimenezsousa lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT monicagutierrezrivas lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT salvadorresino lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy AT veronicabriz lowfrequencyofns5arelevantresistanceassociatedsubstitutionstoelbasviramonghepatitiscvirusgenotype1ainspainacrosssectionalstudy
_version_	1718395015088046080

Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study

Ejemplares similares